Congress voted last year to strip most hemp THC products of their federal legal status, starting November 12. On Saturday morning, the Senate pushed that date to December 11. Here is what the ban actually does, what the vote changed and why this extension is probably the last one.
If you have not been following this fight closely, here is the short version of what is at stake, and then what actually happened.
First: What Is the Hemp Ban?
In 2018, the Farm Bill legalized hemp, defined as cannabis containing no more than 0.3% delta-9 THC by dry weight. Nobody in Congress seemed to anticipate what would happen next. Chemists worked out how to convert legal hemp-derived CBD into intoxicating cannabinoids the statute had not mentioned: delta-8, delta-10, HHC, THC-O. Growers realized THCA flower is not intoxicating until you heat it, which meant it technically fell inside the definition. Beverage makers built a THC seltzer category from scratch.
Within a few years, that gap became a multibillion-dollar industry selling weed-adjacent products in gas stations, smoke shops, liquor stores and grocery aisles, including in states where marijuana itself is still illegal.
Late last year, Congress moved to close it. Tucked into the spending bill that ended the record-long government shutdown was Section 781 of P.L. 119-37, a rewrite of the federal definition of hemp. Trump signed it into law, though his administration would later push Congress to postpone the very restrictions he had approved. The provision was championed by Sen. Mitch McConnell, the same senator who wrote hemp into the 2018 Farm Bill in the first place.
The new rule does two things. It measures total THC, which counts THCA rather than ignoring it. And it caps finished consumable products at 0.4 milligrams per container of total THC plus other cannabinoids with similar effects.
The 0.4-milligram cap, not the word “ban,” is the mechanism. A typical hemp gummy carries 10 milligrams. A THC seltzer carries between 2 and 10. Almost nothing on the market clears 0.4.
The US Hemp Roundtable has estimated roughly 95% of existing hemp cannabinoid products fall outside the new definition. The effective date was November 12, one year after enactment. We broke down the fine print here.
Then Came the Fight Over Delaying It
The hemp industry spent nine months lobbying to get the law changed before it landed. It did not get a rewrite. What it got instead was an attempt at more time.
Senate leaders released a stopgap funding bill on August 2 to keep the federal government open through December 11. Inside it, at the White House’s request, was a provision pushing most of the hemp restrictions to that same date. Cannabinoids that the plant cannot naturally produce would still lose federal hemp status on November 12. Everything else would get 29 extra days.
Sen. Ted Budd, a North Carolina Republican, filed an amendment to strip it out and hold the original date. He called intoxicating hemp a “public health crisis” and held up posters on the Senate floor showing THC packaging that resembled Oreos and Skittles as evidence that the hemp industry’s goal is to make children “addicted to these disguised substances.” His amendment collected 13 cosponsors and threatened to derail the entire funding bill and the Senate’s August recess. We covered that standoff here.
What Happened Saturday
Budd’s amendment died at 3:35 a.m.
The Senate voted 61-32 to table it. The motion came from Sen. Amy Klobuchar, the Minnesota Democrat who wrote the delay provision in the first place. Twenty-four minutes later, the chamber passed the underlying continuing resolution 90-6, according to the Senate’s official record.
That means the Senate bill would push most of the November 12 restrictions to December 11, if the House agrees and Trump signs it. Neither has happened. Until both do, November 12 remains the operative federal date.
Read past the vote count, though, and the week produced four things that matter more than the calendar.
1. Nobody Voted the Way You’d Guess
Start with the roll call, because it scrambles every assumption about who sits where on cannabis policy.
Eleven Democrats voted with Budd to keep his amendment alive: Kirsten Gillibrand, Dick Durbin, Catherine Cortez Masto, Maggie Hassan, Martin Heinrich, Mazie Hirono, Jeff Merkley, Alex Padilla, Jacky Rosen, Adam Schiff and Lisa Blunt Rochester. Republicans including Rand Paul, Steve Daines and Tim Sheehy voted to protect the delay.
Merkley and Padilla lined up with Ted Budd. Rand Paul lined up with Amy Klobuchar. Hemp has managed to scramble both parties at once.
Paul, the delay’s loudest Republican defender, accused his colleagues of wildly exaggerating the risk. He told reporters for the Associated Press and PBS NewsHour after the lunch that the senators pushing to keep the ban on schedule were behaving “like they watched ‘Reefer Madness’ in 1937.”
On the other side, Sen. Tom Cotton called the products “gas-station marijuana candy” during a closed-door Republican lunch that Sen. Josh Hawley later described to MS NOW as a “big blow-up.”
2. The White House Signaled This Is the Last Delay
The most important thing of the week happened three days before the vote, in a room the industry was not in.
James Braid, the White House director of legislative affairs, attended that Republican lunch. Cotton, Sen. Pete Ricketts and Budd pressed him on why the administration had reversed course on a law the president himself signed. According to Axios, NBC News and Punchbowl News, all citing people present, Braid committed that there would be no further delays beyond the one in the funding bill.
The pressure went beyond the lunch. Trump personally called Budd on Tuesday night, after the senator filed his amendment. According to a Senate aide cited in reports of the call, the president discussed setting up federal regulations for hemp but did not directly ask Budd to withdraw it.
December 11 is not a waypoint. On the current signals, it is the cliff.
That matters because the delay exists almost entirely because the administration wanted it. The Hill reported the provision went in at the White House’s request, and Trump has publicly pushed Congress to fix hemp rather than kill it, writing on Truth Social that lawmakers must “get this done RIGHT and FAST, especially for those who saw that CBD helps them.” Take that support away in December and the coalition for another temporary extension gets substantially weaker.
Congress has had nine months to write a permanent fix. It has produced the Barr-Craig Lawful Hemp Protection Act, which would replace the ban with federal potency limits, age restrictions and labeling rules; a competing draft circulating from Rep. James Comer; and a stack of delay proposals. None has advanced far enough to replace the November law.
Why the Reversal Is Being Questioned
There is another reason the White House’s sudden investment in the issue has drawn scrutiny.
In June, White House chief of staff Susie Wiles’s younger daughter Caroline married Bret Worley, the chief executive of MC Nutraceuticals, a hemp company that describes itself as the largest global supplier of cannabinoids. MS NOW reported that Worley’s company urged industry allies to press lawmakers for the delay, and The New York Times reported that once the provision was added to the funding bill, MC Nutraceuticals told prospective customers the industry now had “a seat at the table.”
The White House denies that the family connection influenced its position. Spokesman Kush Desai said Wiles “has never lobbied in favor of this or any other position on hemp with Capitol Hill,” and that the administration is guided by the interests of veterans and patients. Neither Wiles nor Worley responded to requests for comment from MS NOW, and MC Nutraceuticals did not respond to the Times.
None of that establishes that the delay was written to benefit anyone’s business. It does explain why senators in both parties spent the week asking harder questions about an abrupt reversal.
3. The Cannabis Industry Is Split
Hemp groups treated Saturday’s vote as permission to keep building.
“This morning’s vote was a huge turning point in the pursuit of safe, responsible federal regulation,” said Christopher Lackner, founder and president of the Hemp Beverage Alliance, which represents 375 members across the US and Canada. “The next chapter begins today.”
Thomas Winstanley, president of Edibles.com, part of Edible Brands, the parent company of Edible Arrangements, was more measured.
“Congress did not solve the hemp issue today. It preserved the opportunity to solve it correctly. A delay is not a destination.”
Thomas Winstanley, president, Edibles.com
Winstanley said in a statement that the ban would have “increased consumer risk by driving demand toward the illicit market” while undermining farmers, manufacturers and retailers. That is a central argument from the hemp industry, and the Senate just gave it four extra weeks to land.
But parts of the state-licensed cannabis sector treated the same vote as another month of unequal rules. So did a bipartisan coalition of 35 state and territory attorneys general, who sent Congress a letter on August 4 arguing the ban had “protected consumers, provided much-needed regulatory clarity, and preserved legitimate industrial, agricultural, and nonintoxicating hemp markets.”
The logic is not complicated. A licensed operator pays for a state license, mandatory batch testing, compliance staff, seed-to-sale tracking and state cannabis taxes, then watches a hemp company sell a comparable high through ordinary retail with none of that overhead. From inside a dispensary, November 12 does not look like prohibition. It looks like the end of an arbitrage.
From inside a hemp beverage company, the same date looks like the government erasing a legal business built on a law Congress itself wrote in 2018.
Both pressures are real, and the split helps explain why a clean fix has been so hard. Hemp operators are lobbying to preserve a national market. Prohibition groups and parts of the licensed cannabis world are lobbying for the opposite outcome. That makes for an unusual coalition, even if its members arrived there for entirely different reasons.
4. The Medicare Guy Showed Up
The strangest detail of the week got almost no coverage.
On Friday, Mehmet Oz, who runs the Centers for Medicare and Medicaid Services, urged senators to reject Budd’s amendment. His concern was a program his own agency launched in April.
The Substance Access Beneficiary Engagement Incentive lets providers in certain CMS Innovation Center models consult with Medicare beneficiaries about eligible hemp products for symptom control, and furnish those products at the provider’s own expense, up to $500 per beneficiary per year. Medicare does not pay for them. Five accountable care organizations submitted implementation plans for the first performance period.
So Medicare’s own agency is already in the hemp business, and its administrator spent political capital on a Senate floor fight to keep the new hemp law from gutting it.
Here is the part that makes it coherent rather than merely odd. The CMS program already imposes limits of its own. Eligible products must contain no more than 0.3% delta-9 THC. Oral products cannot exceed 3 milligrams per serving of tetrahydrocannabinols, including delta-8, delta-10 and THCA. Cannabinoids the plant cannot naturally produce are excluded outright.
But the incoming federal standard would cap finished hemp products at 0.4 milligrams per container of total THC, including THCA, plus other cannabinoids with similar effects. That is far below the ceiling CMS currently allows, and it would sharply narrow the universe of products the agency can use in its own demonstration. CMS says it will adjust its eligibility definition if federal hemp law changes.
Budd’s response was the sharpest line anyone landed all week. “Why do unregulated intoxicating edibles need to be available at gas stations for CMS to continue studying hemp-derived pain relief?”
It is a fair question, and it points at what the whole fight keeps failing to separate. The full-spectrum tincture a Medicare patient might get through a CMS demonstration and the 100-milligram gummy sold beside the register at a gas station are governed by the same paragraph of federal law. Most of the proposals on the table are attempts to draw a line the current statute does not draw cleanly. None has gotten a vote.
What Still Has to Happen
The delay is not law. It is one chamber’s position, and the House passed its own funding bill with no hemp language in it at all.
When the House returns. It has to decide whether to accept the Senate bill, amend it or negotiate something else.
September 30. Current government funding expires. By then both chambers need to enact identical legislation or the government shuts down.
November 12. Cannabinoids the plant cannot naturally produce lose federal hemp status regardless. That carve-out survived the Senate untouched.
December 11. The 0.4-milligram cap and the rest of the new definition arrive, on the same day the Senate’s own funding bill expires.
The states are on their own clocks either way. Illinois restrictions take effect November 12 under state statute, which no federal stopgap touches. North Carolina is weighing legislation that would write the federal standard into state law. For a company whose immediate problem is Illinois, the federal extension does not move the November 12 state deadline.
Budd has already said he will be back.
“We agreed to ban these drugs nearly 9 months ago, but clearly our fight to stop this scourge is just beginning.”
Sen. Ted Budd, R-N.C.
Nine months produced no framework. The Senate has now offered the industry four weeks more than it had on Friday, but the House still has to agree, the administration has reportedly told senators it is done spending capital on extensions, and the opposition runs from Tom Cotton to Jeff Merkley.
Winstanley had it right. A delay is not a destination. It is also, on the current signals, the last one anybody is handing out.
